-
Commonhold Explained: How New Leasehold Ban Changes Property Ownership in England and Wales
-
Factory Worker Dies in Rare Rectal Explosion Incident in Czechia
-
GIRLBAND! Headline Show at Rough Trade Marks National Breakthrough
-
Decoding UNFCCC Legal Language: The Hierarchy of Verbs in Climate Negotiations
-
Saudi PIF Retains Top Sovereign Wealth Fund Brand Title for Third Year
-
Banff Avenue Transforms into High-End Retail Hub Amid Local Business Concerns
-
Selena Gomez Launches Black Equality Fund to Support Racial Justice Organizations
-
Stemtech Corporation Partners with Fitness Icon Tony Little to Launch Stemtech Biosciences Digital Campaign
-
QNX Brings Physical AI and Next-Generation Software-Defined Vehicle Innovation to CES 2027
-
Vogenx Set to Join the Russell 2000(R), Russell 3000(R), and Russell Microcap(R) Indexes
-
ATWEC Technologies, Inc. (OTCID: ATWT) Engages Michael Gillespie & Associates, PLLC to Audit Fiscal 2026 and 2025 Consolidated Financial Statements and Changes Fiscal Year End to October 31
-
Lumber's Union CBA Agent Launches in Sage Agent Marketplace to Help Simplify Union Payroll Compliance
-
Metano Emerges From Stealth to Unify AI Agent Security Across the Enterprise
-
The 2026 MDaudit Annual Benchmark Report Spotlights AI's Impact on Financial Risk as Payer Denials and Audits Continue an Upward Trajectory
-
MicroVision and Blue-Band to Support $3 Million Federally Funded Intelligent Transportation Initiative in Louisville, Kentucky
-
More Than Half of Teen AI Chatbot Users Use Them Daily, and 46% Say It Feels Like Talking to a Human, New Family Online Safety Institute Research Finds
-
Celtic Bank Selects Infinant to Scale Its Embedded Finance Programs
-
Go Green Global Technologies Corp. Appoints Dennis Beckert as Interim Chief Executive Officer
-
InstaLILY Launches Lily for Sales on Microsoft Dynamics 365, Where Sellers and AI Agents Work Together in Shared Rooms
-
Wave AI, the AI Note Taker for In-Person Meetings, Passes 5 Million Recorded Hours
-
Increasing Electrification Raises Grid Risk and Cost Pressure for Industrial Sites, ABI Research Finds
-
Jerash Holdings Partners with International Finance Corporation (IFC) to Pursue EDGE Gender Certification
-
Lexaria's Human Study GLP-1-H26-7 Completes Dosing as Scheduled
-
Philadelphia Sexual Assault Lawyer David P. Thiruselvam Explains Who Can Be Named in a Civil Sexual Assault Claim
-
Long Island Capital Alliance to Host Technology Capital Forum
-
BlackBerry and Hazard Management Cayman Islands Renew Critical Alerting System for Emergencies and Public Safety
-
Medical Care Technologies Inc. (OTCID:MDCE) Pauses Dilution Through 2027 After Q3 Profitability Rebound and Infinite Auctions Private Sales Exceed $300,000 in Q4
-
Trustpoint Xposure Completes More Than 200 AI Visibility Audits Across Professional Services
-
Making the Most of a Long Weekend Without Leaving Town
-
Bob's Watches Founder Paul Altieri Unveils Private Collection of Vintage Rolex Watches in New Book, "NOT FOR SALE"
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 19
-
Hemogenyx Pharmaceuticals PLC - Chairman Receives Prestigious Award
-
American Critical Minerals Reports High Grade Potash Intersection of 6.55m Grading 38.51 wt.% KCl at its Green River Project, Utah
-
LASE to Premiere Quantum Bullet(TM) at Counter UAS Technology Conference in Washington, D.C.
-
First Canadian Graphite Reports 43.9% Graphitic Carbon Sample and Encouraging Coarse-Flake Characteristics at Zone 13 at Lac Guéret South
-
IRS Shuts Down FIRE Today: What Information Return Filers Need to Know Before the 2027 Filing Season
-
NoHo, Inc. Acquires Four Placer Gold Claims in Clark County, Nevada from Gold Stake Mining Inc.
-
Arrive AI Eliminates All Debt Through Preferred Equity Exchange
-
Gamma Resources Announces Expansion of Mesa Arc Uranium Project in New Mexico to 4,760 Acres, Completes Radon Flux Baseline Survey
-
Golden Minerals Completes Drilling Desierto, Argentina
-
Guanajuato Silver Reports Q3 Operating and Financial Results
-
Helio Corporation Engages CORE IR to Provide Investor Relations, Capital Markets Advisory and Media Relations Services
-
Greene Concepts Connects Consumer Needs with Manufacturing Strategy
-
Karbon-X (OTCQB:KARX) Enters California's Multi-Billion-Dollar Compliance Carbon Market Following CITSS Approval
-
Skilled Nursing Facilities Face 2027 Revenue Cycle Reckoning as Payer Burdens Reshape Admissions and Outsourcing
-
Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
-
multiQure Begins Manufacturing Phase of MQ-201 Gene Therapy for First Huntington's Disease Patients - U.S.-Based Andelyn Biosciences Selected as Manufacturing Partner
-
Nextech3D.ai Reports Fiscal Q2 2027 Financial Results: AI Event Technology Doubles Revenue
-
Who Is the Best MTF Top Surgeon?
-
Kolter Homes Introduces New Nancy Floorplan at Woodland Preserve in Parrish, Florida
MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog
Study demonstrated Ketamir-2 was safe and well tolerated at all dose levels, with a favorable safety and tolerability profile, with no severe or clinically significant adverse effects observed. The drug showed rapid and predictable absorption, a favorable duration of action supporting once-daily dosing, and no CNS side effects typically seen with ketamine.
Study demonstrated Ketamir-2 was safe and well tolerated at all dose levels, with a favorable safety and tolerability profile, with no severe or clinically significant adverse effects observed. The drug showed rapid and predictable absorption, a favorable duration of action supporting once-daily dosing, and no CNS side effects typically seen with ketamine.
MIAMI, FLORIDA / ACCESS Newswire / September 22, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced topline results from the single ascending dose (SAD) portion of its ongoing Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of its lead oral candidate, Ketamir-2, in healthy volunteers.
The randomized, placebo-controlled study enrolled 32 healthy adult participants across four escalating oral dose cohorts (50 mg to 600 mg). The primary endpoints were safety, tolerability, and PK characterization.
Key Pharmacokinetic Findings
Dose-proportional increases in exposure (Cmax and AUC) were observed across all dose levels tested.
Median time to maximum plasma concentration (Tmax) reached within 1-2 hours, consistent across cohorts, confirming rapid and predictable absorption.
Terminal half-life (t½) of Ketamir-2 ranged from 2-5 hours, while its primary active metabolite, nor-Ketamir, demonstrated a longer half-life of 6.5-8.5 hours. This favorable duration of action supports convenient once-daily dosing and may contribute to sustained therapeutic benefit.
This contrasts with oral ketamine, which is characterized by erratic absorption and a much shorter half-life, limiting its clinical use in chronic treatment. The predictable PK profile of Ketamir-2 supports convenient once-daily dosing for patients with neuropathic pain and potentially other CNS conditions.
Safety and Tolerability
Ketamir-2 was generally safe and well tolerated across all four cohorts
No dose-limiting toxicities or serious adverse events were observed
Treatment-emergent adverse events were transient and resolved without intervention
In addition to routine safety assessments, CNS effects were carefully monitored using validated tools (C-SSRS, Bowdle VAS, KSET). Across all SAD cohorts, Ketamir-2no clinically significant adverse effects observed.
Next Steps
Based on the data, MIRA is initiating the multiple ascending dose (MAD) portion of the Phase 1 study in healthy volunteers, to be followed by a Phase 2a trial in patients with neuropathic pain.
Management Commentary
"These first-in-human data clearly demonstrate a favorable safety profile and predictable pharmacokinetics across a wide dosing range," said Erez Aminov, CEO of MIRA. "Importantly, the absence of the hallmark CNS side effects typically associated with ketamine, which we first observed preclinically, has now been confirmed clinically - reinforcing Ketamir-2's differentiated profile. Given the significant unmet need for safe, effective, and non-addictive treatments for neuropathic pain, we believe Ketamir-2 is well positioned as a highly attractive development candidate, and the Company is actively exploring strategic partnering opportunities to accelerate its advancement."
Dr. Itzchak Angel, CSA of MIRA, added: "The Phase 1 pharmacokinetic data demonstrate that Ketamir-2 is rapidly absorbed, predictably metabolized, and suitable for once-daily dosing - a major advantage compared to oral ketamine, which suffers from poor bioavailability and short half-life. Importantly, we were able to confirm in a human clinical study that Ketamir-2 continues to differentiate itself from ketamine by showing a robust safety and pharmacokinetics profile well adapted for its intended use. These findings underscore its potential as a next-generation therapeutic."
About Ketamir-2
Ketamir-2 is a proprietary, orally bioavailable new molecular entity that selectively targets the NMDA receptor (PCP site) with low affinity and shows no significant off-target activity across a broad receptor panel.
Preclinical studies have demonstrated:
Neuropathic pain: Superior efficacy upon oral administration versus ketamine, pregabalin, and gabapentin in gold-standard models, without the dissociative side effects associated with ketamine.
PTSD: In the validated Single Prolonged Stress (SPS) model, Ketamir-2 restored normalized behavior in stressed animals, reversing hallmark PTSD-like behaviors consistent with non-stressed controls. A larger follow-on PTSD study is ongoing.
Depression: Activity in established preclinical models supports the potential of Ketamir-2 as a differentiated treatment for major depressive disorders, including treatment-resistant depression (TRD).
Inflammatory pain (topical formulation): In animal models, a topical formulation of Ketamir-2 demonstrated pain relief equal to injected morphine, underscoring its versatility and non-opioid potential across pain indications.
The U.S. Drug Enforcement Administration's scientific review of Ketamir-2 concluded that it would not be considered a controlled substance or listed chemical under the Controlled Substances Act and its governing regulations.
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline.
For more information, please visit www.mirapharmaceuticals.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and the statements of MIRA's management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at www.sec.gov and on MIRA's website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact:
Helga Moya
[email protected]
(786) 432-9792
SOURCE: MIRA Pharmaceuticals
View the original press release on ACCESS Newswire
T.Wright--AT